Abstract: ¹²³I-β-CIT (2β-carbomethoxy-3β-4-iodophenyl-tropane), a promising agent for imaging central dopamine transporter, has been successfully used in clinical and differential diagnosis and assessment of the magnitude of degeneration of nigrastriatum in Parkinson's disease.However, due to its poor selectivity for dopamine transporter and prolonged imaging intervel (usually 20h after injection), and therefore limits its clinical use. Several new imaging agents have been developed for dopamine transporter in recent years, and siginificantly improved the characterization for imaging dopamine transporter.